

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Kjell OLMARKER et al.)	Group Art Unit: Unassigned
)	
Application No.: Unassigned)	Examiner: Unassigned
)	
Filed: January 17, 2001)	
)	
For: USE OF CERTAIN DRUGS FOR)	
TREATING NERVE ROOT INJURY)	
)	
)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to the examination of the above-identified application on the merits, please
amend the application as follows:

IN THE SPECIFICATION:

Page 4, line 1, please delete "Remicade^R" and insert therefore --REMICADE[®]--;

and

Page 4, line 2, please delete "Enbrel^R" and insert therefore --ENBREL[®]--.

Page 5, line 15, please delete "50 μ g/ml" and insert therefore --50 μ g/ml--;

Page 5, line 17, please delete "CO₂" and insert therefore --CO₂--;

Page 5, line 19, please delete "in situ" and insert therefore --*in situ*--; and

Page 5, line 33, please delete "H₂O₂" and insert therefore --H₂O₂--.

Page 6, line 6, please delete "Ketalar^R" and insert therefore --KETALAR[®]--;

Page 6, line 8, please delete "0.I" and insert therefore --0.1--;

Page 6, line 8, please delete "Stresnil^R" and insert therefore --STRESNIL[®]--;

Page 6, line 10, please delete "Hypnodil^R" and insert therefore --HYPNODIL[®]--;

Page 6, line 11, please delete "Stresnil^R" and insert therefore --STRESNIL[®]--;

Page 6, line 11, please delete "Stesolid^R" and insert therefore --STESOLID[®]--;

Page 6, line 12, please delete "Novum^R" and insert therefore --NOVUM[®]--;

Page 6, line 24, please delete "Ketalar^R" and insert therefore --KETALAR[®]--;

Page 6, line 25, please delete "Pentothal^R" and insert therefore --PENTOTHAL[®]--;

and

Page 6, line 29, please delete "Spongostane^R" and insert therefore
--SPONGOSTANE[®]--.

Page 7, line 25, please delete "Remicade^R" and insert therefore --REMICADE[®]--;

and

Page 7, line 26, please delete "Enbrel^R" and insert therefore --ENBREL[®]--.

Page 9, line 5, please delete "Embrel^R" and insert therefore --ENBREL[®]--;

Page 9, line 6, please delete "Remicade^R" and insert therefore --REMICADE[®]--;

Page 9, line 16, please delete "no" and insert therefore --not--; and

Page 9, line 23, please delete "at" and insert therefore --as--.

Page 10, line 25, please delete "choose" and insert therefore --chose--; and

Page 10, line 27, please delete "choose" and insert therefore --chose--.

Page 12, line 23, please delete "]here" and insert therefore --There--.

REMARKS:

This is a Continuation of International Application No. PCT/SES99/01671, filed 23 September 1999.

The present Amendment corrects typographical errors observed in the specification. These amendments introduce no prohibited new matter.

The Abstract introduces no prohibited new matter and is based on the Abstract of the International Application.

The new claims (claims 1 and 2) have been presented in the interest of advancing prosecution of claims relating to methods of and pharmaceutical compositions for treating nerve disorders mediated by TNF- α .

The subject matter of claims 1 and 2 is supported in the specification at least in the claims as originally filed. No prohibited new matter has been entered with the entry of these claims.

CONCLUSIONS


The foregoing amendments are being made to place the application in better condition for examination. A favorable action on the merits is respectfully solicited.

If there are any fees due in connection with the filing of this Response, please charge the fees to our Deposit Account. If the Examiner has any questions regarding the above-references application, the Examiner is invited to contact the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____


Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: January 17, 2001